SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
October 17, 1996
Mallinckrodt Inc.
(Exact name of registrant as specified in its charter)
New York 1-483 36-1263901
(State or other jurisdiction (Commission (I.R.S. Employer
of incorporation) File Number) Identification No.)
7733 Forsyth Boulevard, St. Louis, MO 63105-1820
(Address of principal executive offices) (ZIP Code)
Registrant's telephone number, (314) 854-5200
including area code
<PAGE>
Item 5. Other Events
A press release was issued October 16, 1996. The relevant portion of
the text of that release was as follows:
MALLINCKRODT BOARD INCREASES QUARTERLY DIVIDEND;
FOUR DIRECTORS ELECTED AT COMPANY'S ANNUAL MEETING
ST. LOUIS, Mo., October 16, 1996 -- The board of directors of
Mallinckrodt Group Inc.(NYSE:MKG) today increased the quarterly
dividend on the company's common stock to 16.5 cents per share,
payable December 31, 1996, to shareholders of record at the close of
business onDecember 16, 1996.
A regular $1.00 per share quarterly dividend on
Mallinckrodt's 4 percent cumulative preferred stock, also payable on
December 31, 1996, to shareholders of record at the close of business
on December 16, 1996, was declared at the meeting.
Stockholders attending the company's annual meeting today
were told that recent activities to streamline the company are
virtually complete and are having a positive impact on expense
control. The company expects a solid first quarter before a $6
million one-time R&D charge resulting from a strategic alliance to
develop new magnetic resonance imaging technology. Mallinckrodt's
first quarter earnings will be announced on October 23 and will be in
line with analysts' expectations.
Raymond F. Bentele, Gareth C.C. Chang, Ronald G. Evens,
M.D., and Mack G.Nichols were elected to three-year terms on the
Mallinckrodt Board of Directors. Bentele and Evens were previous
board members.
In other business, stockholders approved shortening the
company's name from Mallinckrodt Group Inc. to Mallinckrodt Inc.
Mallinckrodt Inc. is an international growth company
serving specialty markets in human healthcare and specialty
chemicals. Dedicated to improving healthcare and chemistry, the
company is a major producer of diagnostic imaging agents, medical
devices, pain relief pharmaceuticals, catalysts, and laboratory and
microelectronic chemicals. The St. Louis-based company, with fiscal
1996 net sales of $2.2 billion, sells more than 2,000 products in
more than 100 countries. Mallinckrodt employs about 10,400 people
worldwide. The Mallinckrodt web site address is
<www.mallinckrodt.com>.
[Safe Harbor Statement under the Private Securities
Litigation Reform Act of 1995 -- Except for historical information
contained in this news release, the matters discussed are
forward looking statements that involve risks and uncertainties.
Among the factors that could cause actual results to differ
materially are the following: the effect of business and economic
conditions; the impact of competitive products and pricing; capacity
and supply constraints or difficulties; product development,
commercialization or technological difficulties; the regulatory
and trade environment; and the risk factors reported from time to
time in the company's SEC reports.]
# # #
Mallinckrodt Inc.
ROGER A. KELLER
Vice President, Secretary
and General Counsel
DATE: October 17, 1996
